Category: by paywall status

NIH neuroscientist up to 16 retractions

Stanley Rapoport. Source: NIH

Neuroscientist Stanley Rapoport just can’t catch a break.

Rapoport, who’s based at National Institute on Aging, is continuing to experience fallout from his research collaborations, after multiple co-authors have been found to have committed misconduct.

Most recently, Rapoport has had four papers retracted in three journals, citing falsified data in a range of figures. Although the notices do not specify how the data falsification occurred, Jagadeesh Rao, who was recently found guilty of research misconduct, is corresponding author on all four papers.

Back in December, Rapoport told us that a “number of retractions [for] Rao are still in the works:” Continue reading NIH neuroscientist up to 16 retractions

“Clumsy but genuine errors” prompt PNAS correction

Some accidental mistakes have led researchers to issue a long correction to a 2016 PNAS paper.

According to the notice, when the cell biology paper’s corresponding authors became aware of duplications in two images, they immediately notified the journal and the University of Nottingham. After examining the original data archives, the university found that the authors generated the correct images, but the person who prepared the figures selected the wrong images from the data archive.

According to John Atherton, faculty pro-vice-chancellor for the Faculty of Medicine and Health Sciences at the University of Nottingham in the UK, who oversaw the investigation: Continue reading “Clumsy but genuine errors” prompt PNAS correction

Yikes: Peer reviewer stole (and published) author’s data

A gastroenterology and hepatology journal has retracted a 2017 review after discovering it included data “accessible only during peer review for another journal.”

Although we don’t know the details of this particular case—for instance, how the editors and publisher of Alimentary Pharmacology & Therapeutics learned about the transgression and which author was responsible—the journal acted quickly to retract the paper, which was published online in March.

Here’s the retraction notice for “Systematic review: benefits and harms of transarterial embolisation for treating hepatocellular adenoma:”

Continue reading Yikes: Peer reviewer stole (and published) author’s data

How upset should we get when articles are paywalled by mistake?

Mistakes happen. Including, sometimes, putting articles that should be freely available behind a paywall. This occasionally happens — though likely not with alarming frequency, according to publishing expert Charles Oppenheim, who recently wrote about the issue in Scholarly Kitchen. Still, the costs can literally be high, both for the authors who paid to make their articles free and the readers who must pay unnecessarily. Plus, there are indications that not everyone in the publishing community takes the problem seriously. We spoke with patient advocate and open-access advocate Graham Steel, the editor of a new site that tracks such mistakes, Paywall Watch (also recently profiled by The Scientist).

Retraction Watch: What inspired you to develop this website (not to be confused with another Paywall Watch blog, which tracks subscriptions to media sites)? Did any personal experience with a paywall or some other publishing problem prompt you or any of your co-founders to create the site? What’s the ultimate goal?

Continue reading How upset should we get when articles are paywalled by mistake?

Drug researcher up to ten retractions

A pharmaceutical researcher has received his tenth retraction. The reason, once again: duplicating his previous work.

Giuseppe Derosa, based at the University of Pavia in Italy, lost a 2011 paper this month after journal editors identified “substantial duplication of an earlier published paper.” According to the notice, the authors failed to cite the previous work and to disclose that the manuscript had been published or was under consideration elsewhere.

Derosa has a habit of reusing clinical trial data in multiple papers. He received his first four retractions in 2015 for publishing the same clinical trial results six times—two of those papers were retracted over the summer and two more several months later. By 2016, a fifth from the bunch was retracted (one of the six still stands). Derosa received another retraction, citing duplication (which we covered here and which was not related to the six clinical trials).

Continue reading Drug researcher up to ten retractions

BMJ journal yanks paper on cancer screening in India for fear of legal action

BMJ Global Health has pulled a paper that criticized U.S. research of the effects of cervical cancer screening in India over defamation concerns.

That’s not what the notice on the paper says, however — at the moment, it just reads:

This article has been withdrawn.

However, forwarded email correspondence between the first author and an associate publisher reveals the journal published the paper and planned a press release, then realized it should be reviewed by a legal adviser. When first author Eric J. Suba at Kaiser Permanente San Francisco Medical Center inquired about the status of the paper and any potential press release, he was told the journal could no longer publish it, out of concern they would be taken to court.

Suba told us that, when he learned the paper would be pulled:

Continue reading BMJ journal yanks paper on cancer screening in India for fear of legal action

“There is an injustice in this article”

The editors of a plant biology journal have retracted a 2007 paper because of “an injustice.”

According to the notice, the editors of Cytologia found evidence of “apparent figure manipulation,” and decided to retract the paper.

This marks the 10th retraction for plant biologist Dibyendu Talukdar.

Talukdar, who is first and corresponding author on the 2007 paper and listed at the University of Calcutta in West Bengal, India, received his first retraction last July, which also cited suspected figure manipulation. Earlier this year, Talukdar received eight more retractions in seven different journals, all describing concerns over potential image duplication and manipulation.

Here’s the most recent retraction notice in Cytologia: Continue reading “There is an injustice in this article”

Paper with duplicated image “sequentially builds” on neuroscience work, authors argue

A neurochemistry journal has retracted a paper from a group in China over a duplicated image.

According to the notice, the authors used the same image in the two papers to represent different experimental conditions. The only distinguishing feature between the images: “apparent brightness changes.”

The authors defended their actions, explaining that the research published in Journal of Neurochemistry “sequentially builds” on their previous study in Journal of Neuroinflammation, which they mention in the 2015 paper’s discussion. In the notice, the authors were quoted saying:  Continue reading Paper with duplicated image “sequentially builds” on neuroscience work, authors argue

Journal retracts nine papers in one day by author under investigation at the Weizmann Institute

On April 27, the Journal of Biological Chemistry (JBC) retracted nine papers by a researcher based in Israel, including some dating back to 2000.

The reason: Image manipulation.

Michal Neeman, vice president of The Weizmann Institute of Science, told us that the researcher, Rony Seger, is under investigation following an allegation of misconduct affecting papers in multiple journals.

So far, we’ve found 11 retractions for papers by Seger, a molecular biologist. In the notices, the authors state they have “full confidence” in the findings, and in many instances have replicated the work.

According to Neeman:

Continue reading Journal retracts nine papers in one day by author under investigation at the Weizmann Institute

Authors retract much-debated blockchain paper from F1000

The authors of a popular — and heavily debated — F1000Research paper proposing a method to prevent scientific misconduct have decided to retract it.

The paper was initially criticized for allegedly plagiarizing from a graduate student’s blog — and revised to try to “rectify the overlap.” But according to F1000, it is now being retracted after an additional expert identified problems with the methodology.

Today, F1000 added this editorial note to the paper:

Continue reading Authors retract much-debated blockchain paper from F1000